Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$16.9 million.

  • Cartesian Therapeutics' Free Cash Flow fell 306.45% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.9 million, marking a year-over-year decrease of 42.32%. This contributed to the annual value of -$32.8 million for FY2024, which is 36.21% up from last year.
  • Cartesian Therapeutics' Free Cash Flow amounted to -$16.9 million in Q3 2025, which was up 16.03% from -$20.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Free Cash Flow ranged from a high of $8.2 million in Q3 2024 and a low of -$31.7 million during Q4 2021.
  • In the last 3 years, Cartesian Therapeutics' Free Cash Flow had a median value of -$16.5 million in 2024 and averaged -$13.2 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Free Cash Flow plummeted by 335.26% in 2023, and later spiked by 188.79% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Free Cash Flow (Quarterly) stood at -$31.7 million in 2021, then surged by 62.00% to -$12.1 million in 2022, then slumped by 93.62% to -$23.4 million in 2023, then soared by 66.99% to -$7.7 million in 2024, then crashed by 306.45% to -$16.9 million in 2025.
  • Its Free Cash Flow was -$16.9 million in Q3 2025, compared to -$20.1 million in Q2 2025 and -$24.2 million in Q1 2025.